A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Inclusion Criteria: * Histologically or cytologically documented incurable or metastatic solid tumors of the following types: melanoma, UC, ovarian cancer, colorectal cancer, breast cancer (HR+), or prostate cancer. * Disease has progressed after at least one available standard therapy or no additional curative therapies are available. * Measurable disease per RECIST v1.1 * Eastern cooperative oncology group (ECOG) performance status of 0 or 1 * Adequate hematologic and end organ function determined within 30 days prior to enrollment. * Disease-specific criteria related to the specific tumor type are required. Note: There are additional inclusion criteria. The study center will determine if you meet all of the criteria. Exclusion Criteria: * Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and/or inherited liver disease * Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases * Uncontrolled or symptomatic hypercalcemia * Pregnancy, lactation, or breastfeeding * Prior allogeneic stem cell transplant or solid organ transplant * Prior chimeric antigen receptor therapy or other genetically modified T cell therapy * Active HIV, Hepatitis B, or Hepatitis C infection * Active tuberculosis * Severe infection within 2 weeks prior to enrollment * Major surgical procedure within 4 weeks prior to enrollment or anticipation of need for a major surgical procedure during the study. Note: There are…